clinical trial · NCT05609812
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
Lupus Nephritis (LN)AtaciceptPlacebo
brief summary
The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.
started
Nov 2, 2022
primary completion
Mar 15, 2026
completion
Dec 15, 2028
last updated
May 23, 2025
detailed description
The study will assess atacicept vs. placebo on the impact of renal function. Safety and patient reported outcomes will be clinically assessed. The clinical study is comprised of a 104 week double-blind treatment period, followed by a 52 week open-label treatment period and a 26 week safety follow-up period.
official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Active Lupus Nephritis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol